ZA201001193B - 2-anilinopurin-8-ones as inhibitors of TTK/MPS1 for the treatment of proliferative disorders - Google Patents

2-anilinopurin-8-ones as inhibitors of TTK/MPS1 for the treatment of proliferative disorders

Info

Publication number
ZA201001193B
ZA201001193B ZA201001193A ZA201001193A ZA201001193B ZA 201001193 B ZA201001193 B ZA 201001193B ZA 201001193 A ZA201001193 A ZA 201001193A ZA 201001193 A ZA201001193 A ZA 201001193A ZA 201001193 B ZA201001193 B ZA 201001193B
Authority
ZA
South Africa
Prior art keywords
anilinopurin
mps1
ttk
inhibitors
ones
Prior art date
Application number
ZA201001193A
Other languages
English (en)
Inventor
David Michael Andrews
Clifford David Jones
Iain Simpson
Richard Andrew Ward
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA201001193B publication Critical patent/ZA201001193B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA201001193A 2007-08-23 2010-02-18 2-anilinopurin-8-ones as inhibitors of TTK/MPS1 for the treatment of proliferative disorders ZA201001193B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95750807P 2007-08-23 2007-08-23

Publications (1)

Publication Number Publication Date
ZA201001193B true ZA201001193B (en) 2010-10-27

Family

ID=39951669

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA201001193A ZA201001193B (en) 2007-08-23 2010-02-18 2-anilinopurin-8-ones as inhibitors of TTK/MPS1 for the treatment of proliferative disorders

Country Status (19)

Country Link
US (1) US20110118238A1 (xx)
EP (1) EP2212326A1 (xx)
JP (1) JP2010536841A (xx)
KR (1) KR20100057650A (xx)
CN (1) CN103298814A (xx)
AU (1) AU2008290330A1 (xx)
BR (1) BRPI0815709A2 (xx)
CA (1) CA2696200A1 (xx)
CO (1) CO6260060A2 (xx)
CR (1) CR11295A (xx)
DO (1) DOP2010000064A (xx)
EA (1) EA201000341A1 (xx)
EC (1) ECSP10010034A (xx)
MX (1) MX2010002115A (xx)
NI (1) NI201000032A (xx)
NZ (1) NZ584138A (xx)
SV (1) SV2010003491A (xx)
WO (1) WO2009024824A1 (xx)
ZA (1) ZA201001193B (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
FR2955109B1 (fr) 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TW201219383A (en) 2010-08-02 2012-05-16 Astrazeneca Ab Chemical compounds
CN103443100B (zh) * 2010-12-17 2016-03-23 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的取代的6-咪唑并吡嗪
CA2821829A1 (en) * 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
ES2544609T3 (es) * 2010-12-17 2015-09-02 Bayer Intellectual Property Gmbh Imidazopirazinas 2-sustituidas para uso como inhibidores de Mps-1 y TTK en el tratamiento de trastornos hiper-proliferativos
WO2012080236A1 (en) * 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CA2821834A1 (en) * 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US9212184B2 (en) * 2010-12-17 2015-12-15 Bayer Intellectual Property Gmbh 6-thio-substituted imidazo[1,2-a]pyrazines as Mps-1 inhibitors
CN103608350B (zh) 2011-04-21 2015-11-25 拜耳知识产权有限责任公司 ***并吡啶类化合物
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
WO2013135612A1 (en) 2012-03-14 2013-09-19 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
SG11201408419QA (en) 2012-07-10 2015-01-29 Bayer Pharma AG Method for preparing substituted triazolopyridines
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014195274A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines
US9586958B2 (en) 2013-06-11 2017-03-07 Bayer Pharma Aktiengesellschaft Prodrug derivatives of substituted triazolopyridines
GB201403536D0 (en) * 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
AU2016247476B2 (en) 2015-04-17 2021-12-16 Netherlands Translational Research Center B.V. Prognostic biomarkers for TTK inhibitor chemotherapy
NZ755222A (en) 2016-12-20 2022-07-01 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
US11052091B2 (en) 2016-12-21 2021-07-06 Ono Pharmaceutical Co., Ltd. BRK inhibitory compound
TWI820146B (zh) * 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途
WO2021209055A1 (zh) * 2020-04-17 2021-10-21 成都百裕制药股份有限公司 咪唑啉酮衍生物及其在医药上的应用
KR102409595B1 (ko) * 2020-06-29 2022-06-17 한국과학기술연구원 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체
CZ309356B6 (cs) * 2020-09-15 2022-09-28 Ústav experimentální botaniky AV ČR, v. v. i Substituované purinové sloučeniny jako inhibitory proteinkináz, jejich použití jako léčiva a farmaceutické přípravky obsahující tyto deriváty
WO2022135360A1 (zh) * 2020-12-21 2022-06-30 江苏恒瑞医药股份有限公司 嘌呤酮衍生物、其制备方法及其在医药上的应用
WO2022199547A1 (zh) * 2021-03-22 2022-09-29 成都赜灵生物医药科技有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
WO2023025160A1 (zh) * 2021-08-23 2023-03-02 成都百裕制药股份有限公司 一种咪唑啉酮衍生物的制备工艺及其中间体
WO2023046072A1 (zh) * 2021-09-23 2023-03-30 成都百裕制药股份有限公司 咪唑啉酮衍生物的晶型
WO2024012516A1 (zh) * 2022-07-13 2024-01-18 成都百裕制药股份有限公司 咪唑啉酮衍生物在联合放疗***中的应用
WO2024017220A1 (zh) * 2022-07-20 2024-01-25 成都百裕制药股份有限公司 咪唑啉酮衍生物联合多柔比星在***中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2411975T3 (es) * 2005-01-14 2013-07-09 Janssen Pharmaceutica Nv Pirimidinas heterocíclicas anilladas de 5 miembros como inhibidores de cinasas
WO2006091737A1 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
TWI398252B (zh) * 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途

Also Published As

Publication number Publication date
BRPI0815709A2 (pt) 2017-06-13
CN103298814A (zh) 2013-09-11
CO6260060A2 (es) 2011-03-22
CA2696200A1 (en) 2009-02-26
DOP2010000064A (es) 2010-03-31
EA201000341A1 (ru) 2010-10-29
NZ584138A (en) 2011-10-28
KR20100057650A (ko) 2010-05-31
ECSP10010034A (es) 2010-04-30
JP2010536841A (ja) 2010-12-02
EP2212326A1 (en) 2010-08-04
AU2008290330A1 (en) 2009-02-26
US20110118238A1 (en) 2011-05-19
WO2009024824A1 (en) 2009-02-26
SV2010003491A (es) 2010-07-06
MX2010002115A (es) 2010-06-01
CR11295A (es) 2010-05-28
NI201000032A (es) 2010-12-07

Similar Documents

Publication Publication Date Title
ZA201001193B (en) 2-anilinopurin-8-ones as inhibitors of TTK/MPS1 for the treatment of proliferative disorders
IL201650A0 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
EP2063897A4 (en) KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP2063896A4 (en) KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES
HRP20181608T1 (hr) Korištenje inhibitora pde7 u liječenju bolesti kretanja
HK1129890A1 (en) C-met protein kinase inhibitors for the treatment of proliferative disorders
HK1139036A1 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
ZA201000106B (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
ZA201000087B (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
ZA200906210B (en) 3-Imidazolyl-Indoles for the treatment of proliferative diseases
EP2313091A4 (en) PHARMACEUTICAL COMPOSITIONS WITH RET-HEMMERN AND METHOD FOR THE TREATMENT OF CANCER
HK1166314A1 (en) Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders bace
EP2211854A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS
EP2429292A4 (en) COMPOUNDS AND COMPOSITIONS WITH CDK INHIBITORS AND METHOD FOR THE TREATMENT OF CANCER
EP1981526A4 (en) ADIPONECTIN FOR THE TREATMENT OF VARIOUS DISORDERS
EP2488025A4 (en) SEPIAPTERIC INTREDUCTASE INHIBITION FOR PAIN TREATMENT
ZA201102520B (en) Pyridine and pyrimidine based compounds as wnt signaling pathway inhibitors for the treatment of cancer
EP2139475A4 (en) USE OF PDE7 INHIBITORS IN THE TREATMENT OF
ZA201002167B (en) Treatment regime for proliferative disorders
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
HK1141447A1 (en) Pharmaceutical composition for the treatment of proliferative diseases
IL207046A (en) Quinazoline derivatives for the treatment of cancer-related disorders
HK1232162A1 (zh) 治療疼痛症狀及其它失調的化合物
EP2456437A4 (en) COMBINATION THERAPY FOR TAUOPATHIES
EP2328584A4 (en) TREATMENT OF NEUROLOGICAL DISORDERS USING HUPERZINE